Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway

MLA

Ji-Yeon Lee, et al. “Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.” Diabetes & Metabolism Journal, vol. 45, no. 6, Nov. 2021, pp. 921–32. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....10b03c20392d01f31329b2a4e3ec2fca&authtype=sso&custid=ns315887.

APA

Ji-Yeon Lee, Ji Young Lee, Yong Ho Lee, Byung Wan Lee, Jaehyun Bae, Min Young Lee, Eun Seok Kang, Bong Soo Cha, & Eugene Shin. (2021). Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway. Diabetes & Metabolism Journal, 45(6), 921–932.

Chicago

Ji-Yeon Lee, Ji Young Lee, Yong Ho Lee, Byung Wan Lee, Jaehyun Bae, Min Young Lee, Eun Seok Kang, Bong Soo Cha, and Eugene Shin. 2021. “Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.” Diabetes & Metabolism Journal 45 (6): 921–32. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....10b03c20392d01f31329b2a4e3ec2fca&authtype=sso&custid=ns315887.